Dehaeck U, McGahan CE, Santos JL, Carey MS, Swenerton KD, Kwon JS. The Impact of Geographic Variations in Treatment on Outcomes in Ovarian Cancer. Int J Gynecol Cancer 23(2):282-7, 2013.

Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, Hilpert F, Cervantes A,
Brown J, Lanceley L, Velikova G, Sabate D, Pfisterer J, Carey MS, Beale P, Qian W, Swart AM,
Oza A, Perren T. Standard chemotherapy with or without bevacizumab in
advanced ovarian cancer: quality-of-life outcomes from the
International Collaboration on Ovarian Neoplasms (ICON7)
phase 3 randomised trial. Lancet Oncol 14(3):236-43, 2013.

Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O’Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals
only one functionally deleterious BRCA1 mutation. Molec Oncol 2013 Epub ahead of print.


Canadian Cancer Society Research Institute
Contextual genomics: The foundation for subtype specific approaches to ovarian cancer control
PI: Dr. David Huntsman Co: